Research programme: dihydroorotate dehydrogenase inhibitors - Chelsea Therapeutics

Alternative Names: DHODH inhibitors - Chelsea Therapeutics; I-3D project

Latest Information Update: 27 Jun 2014

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Active Biotech
Developer Lundbeck A/S
Class Small molecules
Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

24 Jun 2014 Chelsea Therapeutics has been acquired and merged into Lundbeck A/S
08 Apr 2008 Chelsea Therapeutics International acquires global rights to I-3D from Active Biotech
02 Nov 2006 Preclinical trials in Rheumatoid arthritis in Europe (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com